CRVO
CervoMed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CRVO
Cervomed Inc.
A company that developing standard-of-care therapies for treatment-resistant solid cancerous tumors
20 Park Plaza, Suite 424, Boston, Massachusetts 02116
--
CervoMed Inc., was incorporated in Delaware on June 18, 2015. The company is a clinical-stage biotechnology company focused on developing treatments for age-related neurological diseases.
Company Financials
EPS
CRVO has released its 2025 Q3 earnings. EPS was reported at -0.84, versus the expected -0.64, missing expectations. The chart below visualizes how CRVO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CRVO has released its 2025 Q3 earnings report, with revenue of 322.57K, reflecting a YoY change of -83.37%, and net profit of -7.73M, showing a YoY change of -62.54%. The Sankey diagram below clearly presents CRVO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
